REG - Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results

Solvonis TherapeuticsAnnouncement

12/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250812:nRSL8744Ua&default-theme=true

RNS Number : 8744U  Solvonis Therapeutics PLC  12 August 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

12 August 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

SVN-SDN-14 PTSD Programme - Positive pre-clinical results with three
high-performing candidates advancing to in vivo studies

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
today announces positive results from pre-clinical screening in its SVN-SDN-14
programme, identifying three high-performing candidates to advance into in
vivo studies.

The SVN-SDN-14 series is a novel class of serotonin ("SERT"), dopamine ("DAT")
and noradrenaline ("NET") modulators designed to enhance pro-social behaviour
and improve therapeutic outcomes for people living with Post-Traumatic Stress
Disorder ("PTSD"), which the Company estimates affects over 20 million people
across UK, US, and main EU markets. By modulating neurochemical pathways
associated with trust, empathy, and social bonding, these compounds aim to
help patients rebuild interpersonal relationships, reduce social isolation,
and engage more effectively in therapy.

In-vitro screening for SERT, DAT, and NET modulation activity identified three
of six synthesised candidates with robust, balanced modulation profiles across
all three neurotransmitter systems. These are precisely the mechanistic
attributes the programme is targeting to deliver a new class of medicine for
trauma-related mental health conditions such as PTSD.

While the Company had previously anticipated selecting a single lead candidate
at this stage, the positive performance of three candidates has delivered an
optimal outcome - a strong, competitive shortlist with multiple best-in-class
contenders. This outcome increases optionality, strengthens the dataset and
enhances the probability of selecting a best-in-class candidate with strong
commercial potential.

The three shortlisted candidates will now advance to the final stage of the
current work package - in vivo preclinical studies.

Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "It is
encouraging to see three candidates with equally strong, balanced SERT, DAT,
and NET modulation profiles. This gives us a solid basis from which to make an
informed choice. The in vivo data will enable us to select the candidate with
the best potential to advance as a new treatment option for PTSD."

Anthony Tennyson, Chief Executive Officer of Solvonis, added: "These results
represent an important step forward for the programme. Having three
high-performing candidates at this stage, rather than a single clear lead,
provides us with greater flexibility and a stronger position from which to
select the most promising option for PTSD."

 

Enquiries:

Solvonis Therapeutics plc (LEI: 2138005PH7OJRCRPUD88)

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder ("AUD") and
Post-Traumatic Stress Disorder ("PTSD")-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFZGMRVMVGKZM